Studying Genes in Women With Hepatitis C Virus, Hepatitis B Virus, Human Papillomavirus, and/or HIV Infection

This study has been completed.
Sponsor:
Information provided by:
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT00897689
First received: May 9, 2009
Last updated: September 4, 2010
Last verified: September 2010
  Purpose

RATIONALE: Studying the genes expressed in samples of blood from women with hepatitis C virus, hepatitis B virus, human papillomavirus, and/or HIV infection may help doctors identify biomarkers related to infections and cancer.

PURPOSE: This research study is looking at genes in women with hepatitis C virus, hepatitis B virus, human papillomavirus, and/or HIV infection.


Condition Intervention
Liver Cancer
Nonneoplastic Condition
Precancerous Condition
Genetic: genetic linkage analysis
Genetic: molecular genetic technique
Genetic: polymerase chain reaction
Other: laboratory biomarker analysis

Study Type: Observational
Official Title: HLA and KIR Associations With Infectious Viral Agents in an HIV Cohort of Women (WIHS)

Resource links provided by NLM:


Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • Infection [ Designated as safety issue: No ]

Estimated Enrollment: 3500
Study Start Date: August 2002
Primary Completion Date: August 2010 (Final data collection date for primary outcome measure)
Detailed Description:

OBJECTIVES:

  • Examine the role of HLA and killer immunoglobulin-like receptors (KIR) in the natural history of human papillomavirus (HPV), hepatitis C virus (HCV), and hepatitis B virus (HBV) in HIV-positive and HIV-negative women.
  • Test the hypothesis that KIR and HLA genotype may play a role in the pathogenesis of HIV, HPV, HCV, and HBV infection.
  • Determine the relationship between KIR and HLA genes and risk of HIV infection, according to likely source of virus exposure (sexual versus IV) and demographic factors such as race.
  • Determine the relationship between KIR and HLA genes and CD4+ cell counts and serum HIV RNA levels.
  • Determine the relationship between KIR and HLA genes and incidence of AIDS and other clinical endpoints, including AIDS-associated malignancies and opportunistic infections.
  • Determine the relationship between KIR and HLA genes and the response to highly active antiretroviral treatment (HAART), as measured by increases in CD4+ T-cell levels, reduction in serum HIV RNA levels, and reduction in AIDS rates.
  • Determine the relationship between KIR and HLA genes and risk of HCV infection among injecting drug users, according to viral subtype and demographic factors, such as race.
  • Determine the relationship between KIR and HLA genes and persistence of HCV infection.
  • Determine the relationship between KIR and HLA genes and incidence of HCV-related end-stage liver disease and/or hepatocellular carcinoma.
  • Determine the relationship between KIR and HLA genes and response to immunotherapy, as measured by viral load and liver function tests.
  • Determine the relationship between KIR and HLA genes and the natural history of HPV and cervical dysplasia in HIV-positive and HIV-negative women.
  • Determine the relationship between KIR and HLA genes and persistence of HBV infection.
  • Determine the relationship between KIR and HLA genes and incidence of HBV-related end-stage liver disease and/or hepatocellular carcinoma.

OUTLINE: This is a multicenter study.

Blood samples are analyzed for genomic DNA isolated from lymphoblastoid B-cell lines or from peripheral blood lymphocytes and used for genotyping of HLA and killer immunoglobulin-like receptors (KIR) genes. High-resolution HLA class I and class II genotyping is performed using the HLA class I genes (HLA-A, -B, -C), which are amplified using polymerase chain reaction (PCR) and sequenced.

Previously collected clinical data is also evaluated. Patients were followed every 6 months on the Women's Interagency HIV Study and underwent physical and gynecological examinations and completed questionnaires. Blood samples, cervical lavage specimens, and cervical cytology samples were also collected at that time.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

DISEASE CHARACTERISTICS:

  • DNA and relevant clinical data from properly consented Women's Interagency HIV Study (WIHS) subjects meeting 1 of the following criteria:

    • HIV positive
    • HIV negative but at high risk of HIV infection

PATIENT CHARACTERISTICS:

  • Not specified

PRIOR CONCURRENT THERAPY:

  • Not specified
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00897689

Locations
United States, Maryland
Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office
Bethesda, Maryland, United States, 20892-1182
Sponsors and Collaborators
Investigators
Principal Investigator: Stephen J. O'Brien National Cancer Institute - Frederick
  More Information

Additional Information:
No publications provided

ClinicalTrials.gov Identifier: NCT00897689     History of Changes
Other Study ID Numbers: CDR0000594251, NCI-02-C-N253
Study First Received: May 9, 2009
Last Updated: September 4, 2010
Health Authority: United States: Federal Government

Keywords provided by National Cancer Institute (NCI):
adult primary liver cancer
adult primary hepatocellular carcinoma
high-grade squamous intraepithelial lesion
low-grade squamous intraepithelial lesion
HIV infection
human papilloma virus infection
hepatitis B infection
hepatitis C infection

Additional relevant MeSH terms:
HIV Infections
Hepatitis
Hepatitis A
Hepatitis B
Hepatitis C
Liver Neoplasms
Precancerous Conditions
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Liver Diseases
Digestive System Diseases
Hepatitis, Viral, Human
Enterovirus Infections
Picornaviridae Infections
Hepadnaviridae Infections
DNA Virus Infections
Flaviviridae Infections
Digestive System Neoplasms
Neoplasms by Site
Neoplasms

ClinicalTrials.gov processed this record on February 26, 2013